No unexpected safety signals were found in an integrated analysis of data from three clinical trials of ixekizumab in patients with psoriatic arthritis (PsA). Exposure to ixekizumab over 1,822.2 patient years was evaluated across data from the SPIRIT-P1, SPIRIT-P2 and SPIRIT-P3 trials. The incidence rates for serious adverse events and serious infections remained stable over time, whereas the incidence rates for general infections and injection-site reactions decreased with exposure to ixekizumab. The main opportunistic infections reported were herpes zoster and oral or oesophageal Candida.
References
Original article
Combe, B. et al. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res. Ther. 22, 14 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clarke, J. Long-term safety of ixekizumab confirmed in PsA. Nat Rev Rheumatol 16, 126 (2020). https://doi.org/10.1038/s41584-020-0383-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-0383-7
